BlackRock
BNTC icon

BlackRock’s Benitec Biopharma BNTC Stock Holding History

BlackRock’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.8M Buy
1,407,138
+221,397
+19% +$2.63M ﹤0.01% 3299
2026
Q1 		$12.6M Buy
1,185,741
+193,394
+19% +$2.24M ﹤0.01% 3351
2025
Q4 		$13.4M Buy
992,347
+46,832
+5% +$648K ﹤0.01% 3321
2025
Q3 		$13.3M Buy
945,515
+226,825
+32% +$2.89M ﹤0.01% 3309
2025
Q2 		$8.41M Buy
718,690
+534,264
+290% +$7.47M ﹤0.01% 3498
2025
Q1 		$2.4M Buy
184,426
+10,673
+6% +$129K ﹤0.01% 3937
2024
Q4 		$2.19M Buy
173,753
+145,515
+515% +$1.57M ﹤0.01% 4005
2024
Q3 		$260K Buy
28,238
+234
+0.8% +$2.09K ﹤0.01% 4471
2024
Q2 		$196K Buy
+28,004
New +$207K ﹤0.01% 4553
2022
Q2 		– Sell
-1,150
Closed -$46K – 5856
2022
Q1 		$46K Sell
1,150
-56
-5% -$2.32K ﹤0.01% 5423
2021
Q4 		$53K Buy
1,206
+31
+3% +$1.73K ﹤0.01% 5390
2021
Q3 		$71K Sell
1,175
-231
-16% -$15.2K ﹤0.01% 5227
2021
Q2 		$101K Buy
+1,406
New +$110K ﹤0.01% 5042

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock's BNTC Position: Q2 2026 in Review

BlackRock increased its Benitec Biopharma (BNTC) stake by 19% in Q2 2026, buying an estimated $2.63M and bringing the position to 1,407,138 shares worth $18.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3299.

BlackRock first reported a position in BNTC in Q2 2021 and has held it in 13 quarters since. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • BlackRock held 1,407,138 shares of Benitec Biopharma worth $18.8M as of Q2 2026.
  • BlackRock bought 221,397 Benitec Biopharma shares in Q2 2026, an estimated $2.63M.
  • Benitec Biopharma made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3299 holding.
  • BlackRock first reported a position in Benitec Biopharma in Q2 2021 and has held it in 13 quarters since.
  • 87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.